To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.
The Accelerating Medicines Partnership Alzheimer’s Disease (AMP AD Phase 2) is a new precompetitive public-private partnership that will enable precision medicine research for Alzheimer’s Disease through deep and longitudinal molecular analyses across diverse populations to provide insights that will accelerate the development of therapies for Alzheimer’s Disease.
The Accelerating Medicines Partnership–Schizophrenia is the first neuropsychiatric project of the landmark Accelerating Medicines Partnership program managed by the Foundation for the National Institutes of Health.
Plasticity and Mechanisms of Cognitive Remediation in Older Adults supports a grant for a multicenter clinical research trial on remediating age-related cognitive decline through mindfulness-based stress reduction and exercise.
This project will aim to standardize and validate measurement methods for inflammatory markers associated with Alzheimer’s Disease and/or Major Depressive Disorder to ultimately identify a unique biosignature of disease. The identified biosignature would greatly assist with medication development, patient diagnosing, and patient selection for clinical trials.